ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Where There's Smoke, There's Fire: Uncovering the Role of Inflammation and Fibrosis in CKD Progression in T2D

Chronic kidney disease (CKD) develops in a substantial proportion of patients with type 2 diabetes and significantly increases risk for adverse clinical outcomes, including cardiovascular complications and end-organ damage. The progression of CKD in patients with T2D is driven by the combined effects of metabolic, hemodynamic, and inflammatory and fibrotic factors. Patients with diabetes who have well controlled blood glucose and blood pressure may continue to experience CKD progression, highlighting a need to better understand the role of inflammation and fibrosis, including when triggered by the overactivation of the mineralocorticoid receptor, as a key driver of CKD progression in T2D.